Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Alzheimer patients treated with testosterone in UCLA-led study show improved quality of life


The first study of the effects of testosterone on mood, behavior and psychological health in men with mild Alzheimer disease finds significant improvements in quality of life, as assessed by caregivers.

Led by neuroscientists at the UCLA Alzheimer Disease Research Center and detailed in an early online release of the peer-reviewed journal Archives of Neurology, the double blind, placebo-controlled study used caregiver assessments to evaluate quality of life and used a battery of tests administrated by clinicians to evaluate cognitive skills.

Alzheimer patients treated with testosterone showed significant improvement on a quality-of-life instrument that encompasses memory, interpersonal relationships, physical health, energy, living situation and overall well-being compared with patients who received a placebo, or inactive, medication. However, researchers found no significant differences in memory or other cognitive skills as assessed by tests administered by clinicians.

"The results suggest that testosterone replacement therapy holds potential for improving quality of life of Alzheimer patients and merits further testing with a larger group of patients and with a longer treatment period," said Dr. Po H. Lu, lead author and assistant clinical professor of neurology at the research center and the David Geffen School of Medicine at UCLA.

An estimated 4 million Americans are affected by Alzheimer disease, which causes memory loss, behavior changes and difficulties with thinking.

The 24-week study included 16 male patients diagnosed with mild Alzheimer disease and 22 healthy male control subjects. Each group was randomly subdivided into two treatment arms. One group received daily testosterone treatment in the form of hydroalcoholic gel (75 mg) and other received a gel with no active medication.

The research team assessed cognitive function using the Alzheimer Disease Assessment Scale -- Cognitive Subscale, California Verbal Learning Test, Block Design Subtest, Judgment of Line Orientation and Development Test of Visual-Motor Integration; neuropsychiatric symptoms using the Neuropsychiatric Inventory; global functioning using Clinician’s Interview-based Impression of Change; and quality of life using the Quality of Life -- Alzheimer Disease Scale.

Among patients with the disease, the testosterone-treated group had significantly greater improvements in the scores on the caregiver version of the quality-of-life scale than those who received placebo. No statistically significant differences were seen in cognitive or other scores at the end of the study, though numerically greater improvement or less decline in measures of visual-spatial abilities were found in the group treated with testosterone.

In the healthy control group, a non-significant trend toward greater improvement in self-rated quality of life was observed in the testosterone-treated group compared with placebo treatment.

Primary funding was provided by the John Douglas French Alzheimer’s Foundation. Additional funding was provided by the National Institute on Aging; the UCLA Alzheimer Disease Research Center; the Los Angeles-based Sidell-Kagan Foundation; the University of California, Irvine, Alzheimer’s Disease Research Center; and the Memory and Aging Center at the University of California, San Francisco.

Testosterone and placebo gel were supplied by Marietta, Ga.-based Unimed Pharmaceuticals Inc.

In addition to Lu, other researchers involved in the study were Dr. Donna A. Masterman, Dr. Verna Porter, Dr. Jeffrey L. Cummings and Erin Rebak of UCLA; Ruth Mulnard and Carl Cotman of the University of California, Irvine; Dr. Bruce Miller and Dr. Kristine Yaffe of the University of California, San Francisco; and Dr. Ronald Swerdloff of Harbor-UCLA Medical Center.

Dan Page | EurekAlert!
Further information:

More articles from Health and Medicine:

nachricht Resolving the mystery of preeclampsia
21.10.2016 | Universitätsklinikum Magdeburg

nachricht New potential cancer treatment using microwaves to target deep tumors
12.10.2016 | University of Texas at Arlington

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: New 3-D wiring technique brings scalable quantum computers closer to reality

Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.

"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...

Im Focus: Scientists develop a semiconductor nanocomposite material that moves in response to light

In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.

A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...

Im Focus: Diamonds aren't forever: Sandia, Harvard team create first quantum computer bridge

By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.

"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...

Im Focus: New Products - Highlights of COMPAMED 2016

COMPAMED has become the leading international marketplace for suppliers of medical manufacturing. The trade fair, which takes place every November and is co-located to MEDICA in Dusseldorf, has been steadily growing over the past years and shows that medical technology remains a rapidly growing market.

In 2016, the joint pavilion by the IVAM Microtechnology Network, the Product Market “High-tech for Medical Devices”, will be located in Hall 8a again and will...

Im Focus: Ultra-thin ferroelectric material for next-generation electronics

'Ferroelectric' materials can switch between different states of electrical polarization in response to an external electric field. This flexibility means they show promise for many applications, for example in electronic devices and computer memory. Current ferroelectric materials are highly valued for their thermal and chemical stability and rapid electro-mechanical responses, but creating a material that is scalable down to the tiny sizes needed for technologies like silicon-based semiconductors (Si-based CMOS) has proven challenging.

Now, Hiroshi Funakubo and co-workers at the Tokyo Institute of Technology, in collaboration with researchers across Japan, have conducted experiments to...

All Focus news of the innovation-report >>>



Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

Agricultural Trade Developments and Potentials in Central Asia and the South Caucasus

14.10.2016 | Event News

World Health Summit – Day Three: A Call to Action

12.10.2016 | Event News

Latest News

Resolving the mystery of preeclampsia

21.10.2016 | Health and Medicine

Stanford researchers create new special-purpose computer that may someday save us billions

21.10.2016 | Information Technology

From ancient fossils to future cars

21.10.2016 | Materials Sciences

More VideoLinks >>>